An experimental vaccine could offer fresh hope to women diagnosed with an aggressive and hard-to-treat form of breast cancer, new research suggests.

Researchers say the results mark the first time a vaccine - known as a neoantigen DNA vaccine - has shown such positive results in a clinical trial.

A research team has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.